Royal Marsden NHS Foundation Trust: Colorectal Neoplasms trials

The registry lists 19 Colorectal Neoplasms studies with Royal Marsden NHS Foundation Trust as lead sponsor. 3 are open to participants now and 0 have results posted.

Phase 2 5No phase 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer PatientsRecruitingNCT07673861Not applicable
• Inherited Cancer Early Diagnosis (ICED) StudyRecruitingNCT06163365
• Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal CancerRecruitingNCT04050345
• Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid BiopsiesCompletedNCT04566614
• Lifestyle Changes Using Digital Technology in Colorectal CancerStatus unknownNCT03849352Not applicable
• Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib MonotherapyCompletedNCT03010722
• PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal CancerCompletedNCT02994888
• Study of PRoliferation and Apoptosis in Rectal Cancer, Predictive & Prognostic biOmarkers: Histopathology and ImagingCompletedNCT02486094
• Low Rectal Cancer Study (MERCURY II)Status unknownNCT02005965
• Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) TrialStatus unknownNCT01995942
• Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal CancerCompletedNCT01170299Not applicable
• Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 WeeksStatus unknownNCT01037049Phase 2
• Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal CancerCompletedNCT01022541Phase 2
• Methotrexate in Metastatic Colorectal Cancer With MSH2 DeficiencyTerminatedNCT00952016Phase 2
• SS-GCC1- Screening Study of Genetic Changes in Colorectal CancerStatus unknownNCT00825110
• Modelling Internal Hepatic Movement With an External Abdominal MarkerStatus unknownNCT00299299
• Phase II Fixed Dose Rate Gemcitabine for Advanced or Metastatic Colorectal CancerCompletedNCT00220155Phase 2
• Molecular Markers of Prognosis in Colorectal Cancer PatientsCompletedNCT00220142
• Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal CancerCompletedNCT00220116Phase 2